Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043622 | 0.90 | HSD17B10 (0.51) | CYP1A2POLBCYP2D6HDAC2L3MBTL3 | |
| SCHEMBL20669176 | 0.90 | HSD17B10 (0.51) | CYP1A2POLBCYP2D6HDAC2L3MBTL3 | |
| SCHEMBL22359169 | 0.89 | CYP1A2 (0.68) | CYP1A2POLBCYP2D6GABRDGABRA1 | |
| SCHEMBL20669147 | 0.87 | POLB (0.56) | CYP1A2POLBCYP2D6HDAC2GABRD | |
| SCHEMBL13780351 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2D6L3MBTL3L3MBTL1GABRD | |
| Trifluoroacetic Acid SCHEMBL21981312 | 0.79 | POLB (0.46) | CYP1A2POLBCYP2D6HDAC2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4263453 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2D6L3MBTL3L3MBTL1GABRD | |
| SCHEMBL1725493 | 0.78 | L3MBTL3 (0.47) | CYP1A2CYP2D6HDAC2L3MBTL3L3MBTL1 | |
| SCHEMBL20669138 | 0.77 | CYP2D6 (0.48) | CYP1A2POLBCYP2D6HDAC2GABRD | |
| SCHEMBL20765032 | 0.77 | L3MBTL3 (0.46) | CYP1A2CYP2D6HDAC2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250145643-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| CN-119798279-A | RAS inhibitors | 锐新医药公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4463231-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118922423-A | RAS inhibitors | 锐新医药公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118561952-A | RAS inhibitors | 锐新医药公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334321-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230106174-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-04-06 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235864-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | CYP1A2 2007/4885POLB 4419/4885CYP2D6 815/4885 |
| US-20250145643-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4576/4885POLB 3235/4885CYP2D6 3178/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | CYP1A2 1927/4885POLB 4448/4885CYP2D6 592/4885 |
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4576/4885POLB 3235/4885CYP2D6 3178/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | CYP1A2 4859/4885POLB 2161/4885CYP2D6 4434/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | CYP1A2 1927/4885POLB 4448/4885CYP2D6 592/4885 |
| US-20230106174-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4576/4885POLB 3235/4885CYP2D6 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.